Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.315 per share on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 9, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $7.315 per share, with individual trades ranging from $7.17 to $7.435.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson directly owns 7,167,110 shares of Recursion Pharmaceuticals' Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by insiders are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. The use of a 10b5-1 trading plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates